News Releases

SEATTLE --(BUSINESS WIRE)--Oct. 4, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced two upcoming poster presentations at the Society for

SEATTLE --(BUSINESS WIRE)--Sep. 25, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will present at the Ladenburg Thalmann 2018

ALPN-101 preclinical data to be presented at the 2018 ACR/ARHP Annual Meeting and the 143 rd Annual Meeting of the American Neurological Association SEATTLE --(BUSINESS WIRE)--Sep. 24, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing

SEATTLE --(BUSINESS WIRE)--Aug. 9, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory, and other diseases, provided a corporate update and

SEATTLE --(BUSINESS WIRE)--Aug. 8, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative immunotherapies to treat cancer, autoimmune/inflammatory and other diseases, today reported the grant of an equity inducement award to Mark Litton ,

SEATTLE--( BUSINESS WIRE )--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative immunotherapies to treat cancer, autoimmune/inflammatory, and other diseases, today announced the company will present a business overview and update at the 2018

SEATTLE --(BUSINESS WIRE)--Aug. 6, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative immunotherapies to treat cancer, autoimmune/inflammatory, and other diseases, today announced the company will present a business overview and update at

SEATTLE --(BUSINESS WIRE)--Aug. 6, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative immunotherapies to treat cancer, autoimmune/inflammatory and other diseases, today announced the appointment of life sciences veteran Mark Litton , Ph.D.

SEATTLE & HANGZHOU, China --(BUSINESS WIRE)--Jul. 20, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies to treat cancer, autoimmune/inflammatory, and other diseases, and Laurel Venture Capital , a life

SEATTLE --(BUSINESS WIRE)--May 22, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory, and other diseases, today announced the company will